<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412294</url>
  </required_header>
  <id_info>
    <org_study_id>ECRIN-GC1106-XParTS</org_study_id>
    <secondary_id>UMIN000005857</secondary_id>
    <nct_id>NCT01412294</nct_id>
  </id_info>
  <brief_title>XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer</brief_title>
  <official_title>Phase II Study to Evaluate Efficacy and Safety of Capecitabine/Cisplatin Combination Therapy in Gastric Cancer Patients Who Relapsed After S-1 Adjuvant Chemotherapy (XParTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epidemiological and Clinical Research Information Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate efficacy and safety of Capecitabine/Cisplatin for&#xD;
      gastric cancer patients who relapsed after adjuvant chemotherapy by S-1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      S-1/Cisplatin (SP) is one of the standard treatments of advanced gastric cancer. However,&#xD;
      evidence of SP on gastric cancer recurrence after adjuvant therapy by the same drug (S-1) is&#xD;
      not established. The aim of this study is to evaluate the efficacy and safety of&#xD;
      Capecitabine/Cisplatin (XP) for gastric cancer patients who relapsed after adjuvant&#xD;
      chemotherapy by S-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine, Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Cisplatin</intervention_name>
    <description>Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.&#xD;
Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.</description>
    <arm_group_label>Capecitabine, Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Recurrent gastric cancer histologically confirmed as being adenocarcinoma&#xD;
&#xD;
          2. Age of 20 to 74 years with either gender&#xD;
&#xD;
          3. ECOG Performance Status of 0 to 2&#xD;
&#xD;
          4. Lesions confirmed on imaging within 28 days before registration (not required&#xD;
             measurable lesions as defined in RECIST version 1.1)&#xD;
&#xD;
          5. Post-gastrectomy adjuvant chemotherapy including S-1 for at least 12 weeks including&#xD;
             interruption period&#xD;
&#xD;
          6. Less than 6 months treatment-free interval from completion of adjuvant therapy&#xD;
&#xD;
          7. In case with receiving neoadjuvant chemotherapy, the total dose of CDDP does not&#xD;
             exceed 120mg/m2&#xD;
&#xD;
          8. Treatment-naïve recurrent gastric cancer&#xD;
&#xD;
          9. Life expectancy of at least 3 months after registration&#xD;
&#xD;
         10. Written informed consent&#xD;
&#xD;
         11. Adequate major organ functions within 14 days before registration&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         12. Positive HER2 status&#xD;
&#xD;
         13. Previous treatment with platinum agents after curative surgery&#xD;
&#xD;
         14. Previous history of serious hypersensitivity to fluoropyrimidines or platinum agents&#xD;
&#xD;
         15. Previous history of adverse reactions suggestive of dihydropyrimidine dehydrogenase&#xD;
             (DPD) deficiency&#xD;
&#xD;
         16. More than one cancer at the same time or more than one cancer at different times&#xD;
             separated by a 5-year disease-free interval. However, multiple active cancers do not&#xD;
             include carcinoma in situ or skin cancer which is determined to have been cured as a&#xD;
             result of treatment.&#xD;
&#xD;
         17. Obvious infection or inflammation (pyrexia ≥ 38.0˚C)&#xD;
&#xD;
         18. Active hepatitis&#xD;
&#xD;
         19. Heart disease that is serious or requires hospitalization, or history of such disease&#xD;
             within past year&#xD;
&#xD;
        9) Concurrent illness that is serious or requires hospitalization (intestinal paralysis,&#xD;
        intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, poorly controlled&#xD;
        diabetes mellitus, renal failure, liver disorders, or hepatic cirrhosis)&#xD;
&#xD;
        10) Being treated or in need of treatment with phenytoin or warfarin potassium&#xD;
&#xD;
        11) Chronic diarrhea (watery stool or ≥ 4 times/day)&#xD;
&#xD;
        12) Active gastrointestinal hemorrhage&#xD;
&#xD;
        13) Body cavity fluids requiring drainage or other treatment&#xD;
&#xD;
        14) Clinical suspicion or previous history of metastases to brain or meninges&#xD;
&#xD;
        15) Women who are pregnant, breastfeeding, or potentially (hoping to become) pregnant 16)&#xD;
        Unwillingness to practice contraception&#xD;
&#xD;
        17) Poor oral intake&#xD;
&#xD;
        18) Psychiatric disorders which are being or may need to be treated with psychotropics&#xD;
&#xD;
        19) Otherwise determined by investigators or site principal investigators to be unsuitable&#xD;
        for participation in study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Weeks</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akira Tsuburaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epidemiological and Clinical Research Information Network</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>capecitabine</keyword>
  <keyword>xp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

